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Introduction
Hyperzincaemia and hypercalprotectinaemia (Hz/Hc), a
rare condition within the spectrum of autoinflammatory
diseases, is associated with hepatosplenomegaly, arthritis,
anemia, cutaneous inflammation, and failure to thrive. So
far, no genetic cause has been identified. While the clinical
appearance is heterogeneous, all affected individuals
present with extremely elevated MRP8/MRP14 (calprotec-
tin) serum concentrations (0.9-12.0 g/l (normal range
< 0.001 g/l)).
Objectives
The clinical phenotype of 12 patients was characterized
and compared to 11 patients with classical PAPA syn-
drome. Screening of candidate genes was performed to
identify disease-causing mutations.
Methods
Serum concentrations of MRP8/14 complex were analyzed
in 12 patients with Hz/Hc and compared to 11 PAPA
patients. Candidate exons of these patients were
sequenced. Cytokine profile of 12 patients with PSTPIP1
mutations was analyzed by mulitplex ELISA. MRP8/14
secretion from patient´s PBMCs was measured and activ-
ity of patient`s sera on monocytes evaluated. The clinical
phenotype of all enrolled patients was characterized and
compared.
Results
Ten of twelve patients were heterozygous carriers of a
glutamic acid 250 (GAG)®lysine (AAG)/p.Glu250Lys/
E250K substitution and 1 patient of a glutamic acid 257
(GAG)®lysine (AAG)/p.Glu250Lys/E257K substitution
in exon 11 of the PSTPIP1 gene. MRP8/MRP14 concen-
trations were extremely elevated in these patients (0.9-
12 g/l) compared to eleven patients presenting with
classical PAPA symptoms (0.02-0.35 g/l), whose levels
again were significantly higher compared to normal
controls. Cytokine profiling confirmed the heterogeneity
of PSTPIP1 mutations with a distinct profile for the
Hz/Hc phenotype. MRP8/14 hypersecretion was found
in PBMCs of patients with PSTPIP1 mutations and
the serum of patients with active disease showed co-
stimulatory properties on monocytes activated with
TLR-1 ligands.
Conclusion
The novel PSTPIP1 E250K and E275K mutations cause an
autoinflammatory disorder known as hyperzincaemia and
hypercalprotectinaemia. The disease causes a heteroge-
neous spectrum of symptoms that only partially overlaps
with the presentation of the classical PAPA syndrome.
Elevated MRP8/14 levels are a common hallmark and
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